Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis

Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis

Bibliographic Details
Main Authors:	Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Ali-Frederic Ben-Amor, Carine Savarin, Gilles Defer
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-11-01
Series:	Neurology and Therapy
Online Access:	https://doi.org/10.1007/s40120-023-00564-8

Similar Items

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
by: Pierre Clavelou, et al.
Published: (2023-06-01)

The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
by: Jerome De Sèze, et al.
Published: (2022-12-01)

Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
by: Mohamed AlJumah, et al.
Published: (2020-02-01)

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
by: Peter Rieckmann, et al.
Published: (2021-12-01)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
by: Ricardo Ginestal, et al.
Published: (2023-01-01)

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
by: Bruno Brochet, et al.
Published: (2022-01-01)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
by: Diego Centonze, et al.
Published: (2023-07-01)

Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study
by: Jihad Inshasi, et al.
Published: (2023-06-01)

Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy
by: Massimo Filippi, et al.
Published: (2024-04-01)

Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice
by: S. V. Petrov, et al.
Published: (2022-02-01)

Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice
by: S. V. Petrov, et al.
Published: (2020-08-01)

Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
by: Federico Carlini, et al.
Published: (2023-07-01)

Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients
by: Damiano Paolicelli, et al.
Published: (2022-11-01)

Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis
by: K. Z. Bakhtiyarova, et al.
Published: (2020-06-01)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
by: Vicki E Maltby, et al.
Published: (2021-10-01)

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets
by: N. A. Totolyan, et al.
Published: (2020-10-01)

Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design
by: Peter V. Sguigna, et al.
Published: (2024-04-01)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
by: Nicolas Fissolo, et al.
Published: (2023-07-01)

Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing–remitting multiple sclerosis patients
by: Ivan Arisi, et al.
Published: (2023-12-01)

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
by: Konrad Rejdak, et al.
Published: (2021-11-01)

Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis
by: Florian Rakers, et al.
Published: (2023-11-01)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
by: Leoni Rolfes, et al.
Published: (2023-04-01)

Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy
by: Maddalena Ruggieri, et al.
Published: (2020-08-01)

Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine
by: Rikke Holm Hansen, et al.
Published: (2024-02-01)

CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis
by: Damiano Marastoni, et al.
Published: (2024-02-01)

Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
by: Tobias Moser, et al.
Published: (2021-10-01)

Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis
by: F. T. Aglas-Leitner, et al.
Published: (2022-11-01)

Immunomodulatory Effects Associated with Cladribine Treatment
by: Nicolás Fissolo, et al.
Published: (2021-12-01)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
by: Kimberley Allen-Philbey, et al.
Published: (2023-11-01)

A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
by: Reza Safaei Nodehi, et al.
Published: (2010-03-01)

A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
by: Reza Safaei Nodehi, et al.
Published: (2010-01-01)

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial
by: Gavin Giovannoni, et al.
Published: (2024-02-01)

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
by: Irina Kalatskaya, et al.
Published: (2023-05-01)

Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients
by: M. Mimpen, et al.
Published: (2024-01-01)

Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis
by: Tobias Moser, et al.
Published: (2021-11-01)

Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting
by: Michael Seiberl, et al.
Published: (2023-02-01)

Magnetic Multi-Enzymatic System for Cladribine Manufacturing
by: Guillermo Cruz, et al.
Published: (2022-11-01)

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
by: Yan-Yan Li, et al.
Published: (2024-01-01)

Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients
by: Christoph Ruschil, et al.
Published: (2023-03-01)

Cryptotanshinone ameliorates cladribine-induced cognitive impairment in rats
by: Khadga Raj Aran, et al.
Published: (2023-01-01)